Author

L. van Schie

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Assay:protein sequence· 1 Assay:protein structure· 1

Frequent Co-Authors

N. Callewaert· 5 shared B. Schepens· 3 shared K. Roose· 3 shared X. Saelens· 3 shared C. Lonigro· 2 shared D. Fijalkowska· 2 shared E. Plets· 2 shared G. Michielsen· 2 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

N. Callewaert

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Yeast-based production platform for potent and stable heavy chain-only antibodies

C. Lonigro, H. Eeckhaut, R. A. Symakani, K. Roose, B. Schepens, K. Sedeyn, A.-S. De Smet, J. C. Zavala Marchan, P. Vanhaverbeke, S. Vanmarcke, K. Claes, S. De Cae, H. Demol, S. Devos, D. Fijalkowska, , N. Callewaert

This paper presents a yeast-based platform for producing stable and potent heavy chain-only antibodies, demonstrating its effectiveness with an anti-SARS-CoV-2 example.

bioRxiv · Mar 4, 2024 · PreprintMicrobiology

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike

S. De Cae, I. Van Molle, L. van Schie, S. R. Shoemaker, J. Deckers, N. Debeuf, S. Lameire, W. Nerinckx, K. Roose, D. Fijalkowska, S. Devos, A.-S. Desmet, J. C. Zavala Marchan, T. Venneman, G. H. Ghassabeh, , B. Schepens

The paper identifies ultrapotent SARS-CoV-2-neutralizing nanobodies that bind a conserved epitope on the spike protein, showing therapeutic efficacy in hamsters.

bioRxiv · Mar 10, 2023 · PreprintMicrobiology

Exploration of synergistic action of cell wall-degrading enzymes against Mycobacterium tuberculosis

L. van Schie, K. Borgers, G. Michielsen, E. Plets, M. Vuylsteke, P. Tiels, N. Festjens, N. Callewaert

This study investigates the synergistic effects of cell wall-degrading enzymes against Mycobacterium tuberculosis using a novel microtiter assay and identifies potent enzyme combinations.

bioRxiv · Apr 5, 2021Microbiology

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies

D. Wrapp, D. De Vlieger, K. S. Corbett, G. M. Torres, W. Van Breedam, K. Roose, L. van Schie, VIB-CMB COVID-19 Response Team, M. Hoffmann, S. Pöhlmann, B. S. Graham, N. Callewaert, B. Schepens, X. Saelens, J. S. McLellan

This study isolates and characterizes VHH antibodies that neutralize MERS-CoV, SARS-CoV-1, and SARS-CoV-2 by blocking receptor binding, with structural insights into their epitopes and cross-reactivity.

bioRxiv · Mar 26, 2020Microbiology

Use of a counterselectable transposon to create markerless knockouts from a 18,432-clone ordered M. bovis BCG mutant resource

K. Borgers, K. Vandewalle, A. Van Hecke, G. Michielsen, E. Plets, L. van Schie, S. Vanmarcke, L. Schindfessel, N. Festjens, N. Callewaert

The paper describes a method to generate markerless knockouts from a large transposon mutant library in M. bovis BCG, creating an ordered mutant resource targeting 83% of non-essential genes.

bioRxiv · Oct 24, 2019 · PreprintMicrobiology